ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0807

Safety of Biologic & Targeted Therapies Among Elderly Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

Akhil Sood1, Soham Al Snih1, Vijaya Murthy2, Emilio Gonzalez1 and Mukaila Raji1, 1University of Texas Medical Branch, Galveston, TX, 2University of Texas Medical Branch, League City, TX

Meeting: ACR Convergence 2020

Keywords: Aging, Biologicals, geriatrics, meta-analysis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Recent developments in biologic and targeted therapy have led to better control of disease activity and improved quality of life in patients with rheumatoid arthritis (RA). Many patients with RA are living longer, adding to the growing elderly population. A critical appraisal of extant data from studies on safety of these immunomodulatory therapies in the elderly can inform decision-making by patients and their physicians. We thus conducted a systematic review and meta-analysis of research studies on safety of biologics and targeted therapy in patients aged >60 years with RA.

Methods: We systematically searched Pubmed/Medline and Scopus from January 1, 1999 to June 1, 2020 to identify eligible studies that examined the safety of biologic & targeted therapies in older patients with rheumatoid arthritis. Included studies provided information on patients who received biologic (anti-TNF, IL-1, IL-6, B cell, or T cell) or targeted therapy (Janus kinase inhibitor), patients older than 60 years and a control population (younger users on biologics). Information on overall pooled rates of infections and malignancy was extracted from the studies. Meta-analysis was performed using RevMan software.

Results: We identified 823 studies; of these, 16 were included in the final analysis (12 observational studies and 4 randomized clinical trials) that comprised 8992 older users on biologics and 25,564 younger users of biologics. The pooled prevalence of infections in older and younger users of biologics was 11% and 7%, respectively, yielding a pooled random effects odds ratio of 1.87 (95% CI, 1.67–2.11). Older age was associated with a significant increase in risk of malignancy (OR, 2.32; 95% CI, 1.60–3.35) compared to younger users on biologics. The majority of the eligible studies were conducted in White population.

Conclusion: In a systematic review and meta-analysis, older patients with RA on immunomodulatory therapies were at significantly increased risk of infection and malignancy compared to younger patients on these treatments. Additional studies involving more racially and ethnically diverse cohorts are necessary to broaden our understanding of safety profile of biologics in different populations of older patients with RA. Furthermore, studies which include elderly patients on non-biologics as comparison would be necessary to better assess safety of biologics within elderly population.

Figure 1: Forest plot on risk of infection among older patients (>60 years) on biologics compared to younger patients on biologics

Figure 2: Forest plot on risk of malignancy among older patients (> 60 years) on biologics compared to younger patients on biologics


Disclosure: A. Sood, None; S. Al Snih, None; V. Murthy, None; E. Gonzalez, None; M. Raji, None.

To cite this abstract in AMA style:

Sood A, Al Snih S, Murthy V, Gonzalez E, Raji M. Safety of Biologic & Targeted Therapies Among Elderly Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/safety-of-biologic-targeted-therapies-among-elderly-patients-with-rheumatoid-arthritis-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-of-biologic-targeted-therapies-among-elderly-patients-with-rheumatoid-arthritis-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology